Cargando…
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708883/ https://www.ncbi.nlm.nih.gov/pubmed/36466867 http://dx.doi.org/10.3389/fimmu.2022.1038340 |
_version_ | 1784841038257455104 |
---|---|
author | Minott, Jessica A. van Vloten, Jacob P. Yates, Jacob G. E. Chan, Lily Wood, Geoffrey A. Viloria-Petit, Alicia M. Karimi, Khalil Petrik, James J. Wootton, Sarah K. Bridle, Byram W. |
author_facet | Minott, Jessica A. van Vloten, Jacob P. Yates, Jacob G. E. Chan, Lily Wood, Geoffrey A. Viloria-Petit, Alicia M. Karimi, Khalil Petrik, James J. Wootton, Sarah K. Bridle, Byram W. |
author_sort | Minott, Jessica A. |
collection | PubMed |
description | Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be revealed given their diverse effector functions. Developing an in-depth understanding of the role of antibodies in treatment efficacy is required to optimize immunotherapies and improve the chance of successfully translating them into the clinic. However, analyses of antibody responses can be challenging in the context of antigen-agnostic immunotherapies, particularly in the context of cancers that lack pre-defined target antigens. As such, robust methods are needed to evaluate the capacity of a given immunotherapy to induce beneficial antibody responses, and to identify any therapy-limiting antibodies. We previously developed a comprehensive method for detecting antibody responses induced by antigen-agnostic immunotherapies for application in pre-clinical models of vaccinology and cancer therapy. Here, we extend this method to a high-throughput, flow cytometry-based assay able to identify and quantify isotype-specific virus- and tumor-associated antibody responses induced by immunotherapies using small sample volumes with rapid speed and high sensitivity. This method provides a valuable and flexible protocol for investigating antibody responses induced by immunotherapies, which researchers can use to expand their analyses and optimize their own treatment regimens. |
format | Online Article Text |
id | pubmed-9708883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97088832022-12-01 Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies Minott, Jessica A. van Vloten, Jacob P. Yates, Jacob G. E. Chan, Lily Wood, Geoffrey A. Viloria-Petit, Alicia M. Karimi, Khalil Petrik, James J. Wootton, Sarah K. Bridle, Byram W. Front Immunol Immunology Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be revealed given their diverse effector functions. Developing an in-depth understanding of the role of antibodies in treatment efficacy is required to optimize immunotherapies and improve the chance of successfully translating them into the clinic. However, analyses of antibody responses can be challenging in the context of antigen-agnostic immunotherapies, particularly in the context of cancers that lack pre-defined target antigens. As such, robust methods are needed to evaluate the capacity of a given immunotherapy to induce beneficial antibody responses, and to identify any therapy-limiting antibodies. We previously developed a comprehensive method for detecting antibody responses induced by antigen-agnostic immunotherapies for application in pre-clinical models of vaccinology and cancer therapy. Here, we extend this method to a high-throughput, flow cytometry-based assay able to identify and quantify isotype-specific virus- and tumor-associated antibody responses induced by immunotherapies using small sample volumes with rapid speed and high sensitivity. This method provides a valuable and flexible protocol for investigating antibody responses induced by immunotherapies, which researchers can use to expand their analyses and optimize their own treatment regimens. Frontiers Media S.A. 2022-11-16 /pmc/articles/PMC9708883/ /pubmed/36466867 http://dx.doi.org/10.3389/fimmu.2022.1038340 Text en Copyright © 2022 Minott, van Vloten, Yates, Chan, Wood, Viloria-Petit, Karimi, Petrik, Wootton and Bridle https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Minott, Jessica A. van Vloten, Jacob P. Yates, Jacob G. E. Chan, Lily Wood, Geoffrey A. Viloria-Petit, Alicia M. Karimi, Khalil Petrik, James J. Wootton, Sarah K. Bridle, Byram W. Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
title | Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
title_full | Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
title_fullStr | Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
title_full_unstemmed | Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
title_short | Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
title_sort | multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708883/ https://www.ncbi.nlm.nih.gov/pubmed/36466867 http://dx.doi.org/10.3389/fimmu.2022.1038340 |
work_keys_str_mv | AT minottjessicaa multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT vanvlotenjacobp multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT yatesjacobge multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT chanlily multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT woodgeoffreya multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT viloriapetitaliciam multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT karimikhalil multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT petrikjamesj multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT woottonsarahk multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies AT bridlebyramw multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies |